[Pubmed] Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case S
Posté : 24 mai 2022 12:00
J Clin Neuromuscul Dis. 2022 Jun 1;23(4):210-218. doi: 10.1097/CND.0000000000000391.
ABSTRACT
OBJECTIVES: To evaluate the impact of treatment with eculizumab, a terminal complement inhibitor, on academic and employment status in patients with refractory generalized myasthenia gravis (MG).
METHODS: Case review of 7 US patients.
RESULTS: Six patients were aged ≤65 years; one was a full-time student and the remainder were in employment before MG diagnosis. After diagnosis, all patients gave up work (n = 3) or reduced their study/working hours (n = 4). In the 12 months after eculizumab initiation, patients who had stopped work resumed working in some capacity, whereas those who had changed their work/study hours returned to their original work/study pattern. Patients also experienced a reduction in the number of MG exacerbations, and a clinically significant improvement in MG-Activities of Daily Living scores, and were able to reduce other MG medications.
CONCLUSIONS: These results suggest that treatment with eculizumab may help maintain education/employment activity in patients with refractory generalized MG.
PMID:35608645 | DOI:10.1097/CND.0000000000000391
Source: https://pubmed.ncbi.nlm.nih.gov/3560864 ... 5&v=2.17.6